Nuvation Bio
8 articles with Nuvation Bio
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations Officer
6/1/2021
Experienced technical operations and CMC leader brings scientific and strategic expertise in oncology drug development and life cycle management
-
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference - May 26, 2021
5/26/2021
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced that David Hung, M.D., founder and chief executive officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 9:00 a.m. ET.
-
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update
5/17/2021
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2021, and provided a business update.
-
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas
3/11/2021
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor,
-
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company
2/10/2021
Combined company renamed Nuvation Bio Inc., will be listed on the New York Stock Exchange under ticker symbol "NUVB" Strong cash position of approximately $830 million includes approximately $646 million held in Panacea's trust account and from concurrent private financings NEW YORK , Feb. 10, 2021 /PRNewswire/ -- Nuvation Bio I
-
Nuvation Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/8/2021
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that David Hung , M.D., founder, president and chief executive officer, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Jan
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.